Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Capricor Therapeutics
Biotech
Capricor shares more data for DMD therapy after initiating BLA
Capricor is now testing deramiocel in a phase 3 trial, HOPE-3, which plans to enroll up to 102 patients and is set to wrap up in Dec. 2026.
Darren Incorvaia
Oct 11, 2024 11:50am
Capricor sells Europe rights to late-stage DMD therapy for $35M
Sep 18, 2024 5:55am
Capricor culls COVID-19 vax work, readies for phase 3 DMD trial
Mar 11, 2022 8:00am
Capricor, Nippon ink $705M biobucks deal for phase 3 DMD therapy
Jan 25, 2022 5:00am
Capricor finds efficacy in older Duchenne patients in phase 2
Sep 24, 2021 7:00am
